Participants will be monitored for more than two years, but the first set of results are expected in six months’ time.
The vaccines to begin the Phase 3 trial of the German CureVac vaccine are now in Mexico. This phase will be carried out in cooperation with TecSalud, the health care system of Tecnológico de Monterrey.
CureVac’s candidate vaccine is one of the most advanced in the world. Its Phase 3 clinical trials are being conducted in 29 study centers in Argentina, Belgium, Colombia, the Dominican Republic, Germany, the Netherlands, Panama, Peru, and now in Mexico. Around 36,500 people will participate in these countries.
8,000 volunteers are expected to participate in Mexico, which makes up about 20% of the total sample size.
During the announcement, Foreign Secretary Marcelo Ebrard highlighted that the initial goal of the government’s strategy was to carry out as many Phase 3 clinical trials of various vaccine projects as possible in Mexico. CureVac is now one of four developments that are already being implemented nationwide, along with vaccines from the American Novavax company, the Chinese CanSino Biologics pharmaceutical company, and Janssen from the American Johnson & Johnson company.
Guillermo Torre, the rector of TecSalud and Vice-President of Research at Tecnológico de Monterrey, highlighted the importance of working in cooperation with the authorities, private initiative, academia, and civil society to stop the spread of the pandemic.
“I would like to underline the importance of collaborating in both public and private sectors for the common good. I would say that the vaccine is very important, because the vaccination strategy is going to be a watershed for the pandemic, but it’s also a very important message: this effort that we’ve made today with the arrival of the vaccine also sends a signal to all Mexicans that it’s very important to work together in good faith and unity to do great things for Mexico,” said Dr. Guillermo Torre.
The clinical study will be carried out in six centers: 1) TecSalud’s Zambrano Hellion Hospital, 2) PanAmerican Clinical Research México S.A. de C.V., 3) Panamerican Clinical Research Mexico – Guadalajara, 4) Specialized Medicine Unit, 5) CAIMED – Mexico, 6) Salvador Zubirán National Institute of Medical Sciences and Nutrition.
Participants will be monitored for more than two years to determine the long-term safety of the vaccine, as well as its efficacy. The first set of results are expected within six months.